| | | | | | | | | | | | | | | | |
| |
![Collapse](/DXR.axd?r=1_87-p7f1t) | Issue Date FY: 2024 ( Subtotal = $105,028,673 ) (Continued on the next page) |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284291 | Fertility legislation and unmet needs: Exploring intervenable barriers for quality oncofertility care among adolescent and young adult cancer patients | 001 | 2 | NIH | 6/13/2024 | -$92,664 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284291 | Fertility legislation and unmet needs: Exploring intervenable barriers for quality oncofertility care among adolescent and young adult cancer patients | 000 | 2 | NIH | 4/26/2024 | $92,664 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R03DK138231 | The role of the mesenchymal niche in intestinal crypt fission | 000 | 1 | NIH | 2/7/2024 | $125,700 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA264296 | Exploiting Oncogenic Chromatin Regulators in Cancer Initiation and Progression | 000 | 3 | NIH | 12/21/2023 | $92,304 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AI183717 | Symposium on the Immune System of Bacteria | 000 | 1 | NIH | 3/5/2024 | $7,500 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA274706 | SIRT1 Regulates RNA Stability to Promote Breast Cancer | 000 | 3 | NIH | 5/23/2024 | $87,804 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA283279 | Molecular Dynamics of Glioma Formation and DNA Damage Response by Mutant IDH1 | 000 | 1 | NIH | 5/6/2024 | $299,403 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R61CA278449 | New Chemical Tools for Covalent Drug Discovery | 000 | 1 | NIH | 1/30/2024 | $249,647 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21AG080395 | Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy | 001 | 2 | NIH | 5/6/2024 | $26,700 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21AG080395 | Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy | 000 | 2 | NIH | 12/11/2023 | $240,300 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 001 | 2 | NIH | 5/24/2024 | $4,784 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32GM149115 | Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | 000 | 2 | NIH | 1/22/2024 | $69,500 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG075837 | Contribution of a novel OPN-producing CD11c+ microglial subset to AD | 000 | 1 | NIH | 1/16/2024 | $505,974 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 002 | 3 | NIH | 4/16/2024 | $34,005 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA266194 | Selective disruption of histone deacetylase complexes using protein interaction modulators | 001 | 3 | NIH | 1/12/2024 | $612,114 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 001 | 2 | NIH | 4/16/2024 | $34,924 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial | 000 | 2 | NIH | 1/5/2024 | $628,653 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99DK133502 | Mechanisms of mitochondrial-ER communication during dietary and thermal induced stress | 000 | 2 | NIH | 6/20/2024 | $90,000 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AG086369 | Mitoribosome protein translation signaling and survival mechanisms | 000 | 2 | NIH | 6/27/2024 | $727,340 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA289304 | Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer | 000 | 1 | NIH | 4/5/2024 | $497,544 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA278980 | Dissecting Convergent Somatic and Germline Alterations that Mediate the Origins and Evolution of Kidney Cancer | 000 | 1 | NIH | 12/29/2023 | $728,817 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA286749 | Improving response prediction to neoadjuvant therapy in pancreatic cancer | 000 | 2 | NIH | 7/19/2024 | $288,565 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA287050 | Harnessing Exercise to Enhance Immunity and Boost Immunotherapy Outcomes in Patients with Lung Cancer | 000 | 1 | NIH | 1/18/2024 | $163,448 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA283395 | Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma | 000 | 2 | NIH | 5/7/2024 | $677,914 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI165666 | Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases | 001 | 2 | NIH | 7/17/2024 | $664,312 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK136640 | Regulatory mechanisms of mitochondrial cristae biogenesis and thermogenic function | 000 | 2 | NIH | 7/10/2024 | $664,134 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA279888 | Targeting Menin Protein Stability In AML | 000 | 2 | NIH | 3/12/2024 | $129,600 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI176904 | Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds | 000 | 2 | NIH | 6/12/2024 | $825,965 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00AG078230 | Effects of Extracellular Mechanics on Mechanosensory and Central Neuron Function | 000 | 5 | NIH | 1/22/2024 | $93,370 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00AG078230 | Effects of Extracellular Mechanics on Mechanosensory and Central Neuron Function | 001 | 5 | NIH | 1/30/2024 | $860 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 001 | 2 | NIH | 4/24/2024 | $22,995 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 2 | NIH | 11/3/2023 | $413,929 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HL171973 | Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia | 000 | 1 | NIH | 12/1/2023 | $445,000 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA253731 | Targeting Oncogenic Drivers in Cancer | 000 | 5 | NIH | 1/17/2024 | $93,150 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K01DK132455 | The Role of Mitochondrial TNAP in Adaptive Thermogenesis | 000 | 2 | NIH | 11/8/2023 | $127,781 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 001 | 3 | NIH | 5/9/2024 | $53,205 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R00CA266921 | SESORRS endoscopy for the staging and evaluation of colorectal cancer | 000 | 3 | NIH | 1/5/2024 | $248,999 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 1 | NIH | 1/9/2024 | $735,360 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA276044 | Liquid biopsy in myeloma to inform outcome and treatment decisions | 001 | 2 | NIH | 4/16/2024 | $20,359 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA276044 | Liquid biopsy in myeloma to inform outcome and treatment decisions | 000 | 2 | NIH | 1/12/2024 | $366,458 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21EB035247 | Improving prognosis prediction and therapy selection for cutaneous squamous cell carcinomas using artificial intelligence | 000 | 1 | NIH | 7/17/2024 | $693,156 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA286345 | In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity | 000 | 1 | NIH | 1/24/2024 | $268,059 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 001 | 4 | NIH | 12/4/2023 | $463,940 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 001 | 26 | NIH | 4/16/2024 | $26,432 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 000 | 26 | NIH | 11/16/2023 | $475,795 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA247375 | CDC7 kinase in normal and cancer cells: potential implications for cancer treatment | 001 | 5 | NIH | 4/17/2024 | $23,308 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA247375 | CDC7 kinase in normal and cancer cells: potential implications for cancer treatment | 000 | 5 | NIH | 11/13/2023 | $419,566 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 001 | 3 | NIH | 5/21/2024 | $112,495 |
| 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 3 | NIH | 10/31/2023 | $1,060,855 |
|